Patient eligibility guidelines
See NICE guideline recommendations for which patients are eligible to received treatment with glucagon-like peptide-1 (GLP-1) receptor agonists
See NICE guideline recommendations for which patients are eligible to received treatment with glucagon-like peptide-1 (GLP-1) receptor agonists
NICE recommends that Glucagon-like peptide-1 (GLP-1) receptor agonists are prescribed for adults with insufficiently controlled Type 2 diabetes (when triple therapy with metformin and 2 other oral drugs is not effective, or when metformin is contraindicated) who:1
- Have a Body Mass Index (BMI) of 35kg/m2 or higher (adjusted accordingly for people from Black, Asian and other minority ethnic groups) and has additional psychological or medical conditions that are related to obesity1
- Have a BMI lower than 35kg/m2 and for whom:1
- Insulin therapy would have significant occupational implications, or
- Weight loss could benefit other significant obesity related comorbidities
For full patient eligibility criteria and prescribing information please see the NICE or SmPC guidelines.1,2
BMI, Body Mass Index; GLP-1 RA, glucagon-like peptide-1 receptor agonist; NICE, National Institute of Clinical Excellence; SmPC, Summary of Product Characteristics.
1. NICE Guidelines, available from: https://www.nice.org.uk/guidance/ng28. Accessed November 2024.
2. Zegluxen® (liraglutide) Summary of Product Characteristics.
000697553 | December 2024